# Workflow 3: High-Throughput Virtual Screening

## Overview
This workflow demonstrates virtual screening for drug discovery by computationally evaluating compound libraries against therapeutic targets. We focus on cutting-edge targets with immediate clinical relevance and established structural biology.

## Target Selection Analysis

### 🎯 **Selected Target: GLP-1 Receptor**
**Why GLP-1 Receptor is Compelling (2024-2025):**
- **Breakthrough Timing**: Novo Nordisk Phase III trials (EVOKE/EVOKE Plus) results due September 2025
- **Paradigm Shift**: Diabetes drug (semaglutide/Ozempic) showing unexpected benefits in Alzheimer's patients
- **Novel Mechanism**: Weight loss + neuroprotection pathway for brain diseases
- **Market Potential**: Could revolutionize Alzheimer's treatment ($100B+ market)

### 🏗️ **Structural Coverage Available:**
| PDB ID | Description | Resolution | Use Case |
|--------|-------------|------------|----------|
| **7S15** | GLP-1R + Pfizer small molecule | Cryo-EM | ✅ **Best for virtual screening** |
| **7RG9** | Apo form (ligand-free) | Cryo-EM | Clean binding site |
| **5NX2** | Full-length crystal structure | 3.7Å X-ray | Traditional docking |
| **7KI0** | Semaglutide-bound complex | Cryo-EM | Reference for validation |
| **6X18** | GLP-1 peptide bound | Cryo-EM | Native ligand state |

### 🎲 **Alternative Targets Considered:**
| Target | Rationale | Structural Data | Market Status |
|--------|-----------|-----------------|---------------|
| **PD-L1** | 2024 FDA breakthrough (cosibelimab), fewer side effects than PD-1 inhibitors | 100+ PDB structures | Established $100B+ |
| **KRAS G12C** | "Undruggable" target conquered 2021-2024, multiple approvals | Multiple co-crystal structures | Proven success |
| **TYK2** | JAK/TYK2 pathway, multiple 2024 approvals in inflammatory diseases | Good structural coverage | Growing market |

## Virtual Screening Strategy Comparison

### **Screening Approaches Evaluated:**

| Strategy | Target | Library | Size | Timeline | Risk | Innovation |
|----------|--------|---------|------|----------|------|------------|
| **1. Drug Repurposing** | GLP-1R | FDA-approved drugs | ~5K | 2-5 years | Medium | Medium |
| **2. Natural Products** | GLP-1R | Natural compounds | ~200K | 5-10 years | High | High |
| **3. Lead Discovery** | PD-L1 | Lead-like library | ~2M | 10-15 years | Low | High |

### ✅ **Selected Strategy: GLP-1 Receptor + FDA Drug Repurposing**
**Rationale:**
- **Speed**: Fastest path to clinic (compounds already proven safe)
- **Relevance**: Aligns with current breakthrough research
- **Feasibility**: Manageable library size for demonstration
- **Impact**: High clinical relevance if successful

## Implementation Plan

### **Phase 1: Target Preparation**
- Download GLP-1 receptor structure (PDB: 7S15)
- Clean and prepare for docking
- Define binding site from co-crystallized ligand

### **Phase 2: Library Preparation** 
- Download FDA-approved drug database (~5,000 compounds)
- Convert to appropriate formats (SDF → PDBQT)
- Filter for drug-likeness and ADMET properties

### **Phase 3: Virtual Screening**
- Batch docking using AutoDock Vina
- Score and rank compounds
- Analyze binding poses and interactions

### **Phase 4: Results Analysis**
- Generate interactive dashboards
- Compare with known GLP-1 agonists
- Identify promising repurposing candidates

## Pipeline Structure
```
GLP-1 Structure (PDB) + FDA Drug Library → AutoDock Vina Screening → Results Analysis → Repurposing Candidates
```

## Directory Structure
```
3_virtual_screening/
├── 1_glp1_fda_repurposing/
│   ├── structures/                # GLP-1 receptor PDB files
│   │   ├── 7s15_glp1r.pdb        # Primary screening structure
│   │   └── 7rg9_apo.pdb          # Alternative apo structure
│   ├── inputs/
│   │   ├── fda_drugs_library/     # FDA-approved compounds
│   │   ├── job_config.json        # Screening parameters
│   │   └── job_script.sh          # Batch docking script
│   └── results/                   # Screening outputs and analysis
└── README.md
```

## Clinical Context: The GLP-1 Alzheimer's Connection

### **Scientific Background:**
- **Current Status**: GLP-1 receptor agonists (semaglutide, liraglutide) approved for diabetes/obesity
- **Breakthrough Discovery**: Unexpected cognitive benefits observed in diabetic patients
- **Mechanism**: GLP-1 receptors in brain involved in neuronal survival and glucose metabolism
- **Clinical Trials**: Major pharma companies now testing GLP-1 drugs for Alzheimer's

### **Repurposing Opportunity:**
If successful, this virtual screening could identify additional FDA-approved drugs that:
1. **Target GLP-1 pathway** through alternative mechanisms
2. **Cross blood-brain barrier** more effectively than current drugs  
3. **Provide combination therapy** options with existing treatments
4. **Offer faster clinical translation** due to established safety profiles

This represents a perfect example of how computational drug discovery can accelerate the translation of breakthrough biological insights into new therapeutic options.

---

## Testing Strategy & Implementation Plan

### Current Status Analysis (September 2025)

**Achievements:**
- ✅ FDA drug library prepared (4,278 compounds)
- ✅ GLP-1 receptor structures ready (7S15, 7RG9)
- ✅ Partial compound conversion (1,603 PDBQT files)
- ✅ Complete AutoDock Vina pipeline script

**Critical Issues Identified:**
- ⚠️ **Conversion Bottleneck**: 63% conversion failure rate (4,278 → 1,603)
- ⚠️ **Scale Challenge**: Full dataset too large for initial validation
- ⚠️ **No Validation**: No completed screening runs yet

### 🧪 **Phase 1: Small Dataset Validation (Priority)**

**Objective**: Validate complete pipeline with manageable dataset

**Testing Approach:**
```bash
# Step 1: Create small test subset
mkdir -p testing/small_dataset_50/
mkdir -p testing/small_dataset_50/inputs/
mkdir -p testing/small_dataset_50/outputs/

# Step 2: Select 50 diverse compounds
# - Include known drugs with different molecular properties
# - Mix of successful + failed conversion candidates
# - Include positive controls (known GLP-1 compounds)
```

**Test Dataset Composition (50 compounds):**
- 30 successfully converted PDBQT files (validation baseline)
- 15 problematic SDF files (troubleshooting targets) 
- 5 known GLP-1 agonists (positive controls: semaglutide analogs)

**Success Criteria:**
- [ ] 100% conversion rate for test set
- [ ] All 50 compounds dock successfully
- [ ] Results ranking makes biochemical sense
- [ ] Processing time < 30 minutes

### 🔍 **Phase 2: Conversion Failure Investigation**

**Root Cause Analysis Plan:**

1. **File Format Issues**
   - Check SDF structure validity
   - Identify problematic molecular features
   - Test alternative conversion tools

2. **OpenBabel Limitations**
   - Try RDKit for failed compounds
   - Test different conversion parameters
   - Handle stereochemistry issues

3. **Molecular Complexity**
   - Filter by molecular weight (< 500 Da)
   - Remove unusual functional groups
   - Handle metal complexes separately

**Systematic Testing:**
```bash
# Create conversion diagnostic script
python3 diagnose_conversion_failures.py \
  --input_sdf fda_drugs_sdf/ \
  --successful_pdbqt ligands_pdbqt/ \
  --output_report conversion_analysis.csv
```

### 🚀 **Phase 3: Incremental Scaling Strategy**

**Progressive Dataset Expansion:**

| Phase | Dataset Size | Focus | Timeline |
|-------|--------------|-------|----------|
| 3A | 100 compounds | Pipeline optimization | Week 1 |
| 3B | 500 compounds | Performance benchmarking | Week 2 |
| 3C | 1,500 compounds | Current successful set | Week 3 |
| 3D | 3,000+ compounds | Extended library | Week 4+ |

**Performance Benchmarks:**
- Conversion rate target: >95%
- Docking success rate: >90%
- Processing time: <2 hrs per 500 compounds

### 🎯 **Phase 4: Full Production Pipeline**

**Production Readiness Checklist:**
- [ ] Automated error handling and recovery
- [ ] Progress monitoring and logging
- [ ] Result validation and quality control
- [ ] Comparison with literature benchmarks

**Quality Control Measures:**
1. **Sanity Checks**: Compare with known GLP-1 binders
2. **Statistical Validation**: Score distribution analysis
3. **Chemical Feasibility**: Filter impossible binding poses
4. **Literature Validation**: Cross-reference with experimental data

### 📋 **Testing Execution Plan**

**Week 1 Priorities:**
1. Set up small test dataset (50 compounds)
2. Debug conversion failures on subset
3. Validate complete pipeline end-to-end
4. Document troubleshooting procedures

**Validation Tests:**
- [ ] Receptor preparation validation
- [ ] Binding site definition accuracy
- [ ] Docking parameter optimization
- [ ] Result interpretation protocols

**Success Metrics:**
- Pipeline reliability: >95% success rate
- Biochemical relevance: Known actives rank in top 10%
- Processing efficiency: <1 minute per compound
- Reproducibility: Consistent results across runs

### 🛠️ **Troubleshooting Guide**

**Common Issues & Solutions:**

| Issue | Symptoms | Solution |
|-------|----------|----------|
| SDF corruption | OpenBabel errors | Re-download, validate format |
| Large molecules | Conversion timeout | Molecular weight filter (<800 Da) |
| Metal complexes | PDBQT generation fails | Remove metals, add back manually |
| Stereochemistry | Multiple conformers | Use RDKit with 3D generation |
| Memory issues | Process crashes | Batch processing in smaller chunks |

This comprehensive testing strategy ensures reliable, validated virtual screening results while systematically addressing the conversion bottleneck.